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Summary 
Mitochondria are dynamic organelles present in virtually all human cells that are needed for a 
multitude of cellular functions, including energy production, control of cell apoptosis and numerous 
biochemical catabolic and synthetic pathways that are critical for cellular health. 
Primary mitochondrial disorders are a group of greater than 200 single gene defects arising from two 
genomes (nuclear and mitochondrial) leading to mitochondrial dysfunction, and are associated with 
extremely heterogeneous phenotypes. Neuromuscular features predominate, but often with multi-
system involvement. 
Clinical suspicion of a mitochondrial disorder should prompt multi-pronged investigation with 
biochemical and molecular genetic studies. Recent wide scale adoption of next generation 
sequencing approaches has led to a rapid increase in the number of disease genes. 
The advances in unravelling the genetic landscape of mitochondrial diseases have not yet been 
matched by progress in developing effective therapies, and the mainstay of care remains supportive 
therapies in a multidisciplinary team setting. 
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Mitochondrial physiology and genetics 
The mitochondrion is an ubiquitous and dynamic cellular organelle with many fundamental roles in 
maintaining normal cellular function. Since the mitochondrion was first described in the late 19th 
century by Altmann and Benda,[1] our understanding of the complexities of mitochondrial function, 
maintenance and replication, and the often catastrophic implications of mitochondrial dysfunction, 
has greatly advanced.  
Mitochondria are composed of a cardiolipin-containing double membrane, with the outer 
mitochondrial membrane surrounding the highly convoluted inner mitochondrial membrane. The 
five protein multi-complexes of the respiratory chain are embedded in the inner membrane, while 
the mitochondrial matrix contains the enzymes of numerous associated metabolic pathways 
including the tricarboxylic acid (TCA) cycle, part of the urea cycle and the machinery of fatty acid 
beta-oxidation.  Complexes I-IV of the respiratory chain/electron transport chain use the reducing 
potential of NADH and FADH2 generated by glycolysis, the TCA cycle and fatty acid oxidation to 
pump protons into the inter-membrane space, thereby generating an electrochemical gradient 
which complex V dissipates to facilitate the phosphorylation of adenosine diphosphate to generate 
adenosine triphosphate (ATP), the fundamental “energy currency” of the cell. In addition to energy 
production, control of cell apoptosis and numerous biochemical synthetic pathways are crucial 
mitochondrial functions that also contribute to the pathophysiology when mitochondrial function is 
deranged.  
Mitochondrial proteins are encoded in genes held in the nuclear DNA and also in the mitochondrial 
DNA (mtDNA). mtDNA is a small 37-gene, ~16.5kb DNA molecule found in multiple copies within the 
mitochondrial matrix.[2] Together, the nuclear and mitochondrial genomes encode more than 1500 
proteins involved in mitochondrial structure and function,[3] including several nuclear genes that 
encode machinery important in the replication and maintenance of the mtDNA.[4]   
Primary mitochondrial diseases are known to be caused by mutations in more than 200 of the 
nuclear genes (figure 1a), inherited in Mendelian patterns (autosomal recessive, autosomal 
dominant or X-linked), and all the 37 mtDNA encoded genes (figure 1b).[5] As mtDNA is only 
acquired from the maternal gamete (ovum) at conception, mtDNA mutations are maternally 
inherited, or may be sporadic de novo events.  
MtDNA has a high copy number (hundreds or thousands of copies per cell) and normal and mutated 
mtDNA often coexist in the same cell, a phenomenon called heteroplasmy. Problems only arise if the 
proportion of mtDNA that is mutated exceeds a threshold. As the level of mutant mtDNA varies 
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between individuals and between tissues in any one individual, different patients with the same 
mtDNA mutation can have very different symptoms 
 
Recognition of Mitochondrial Disease 
Mitochondrial disorders are thought to affect around 1:5000 of the population.[6] There is a wide 
heterogeneity in the clinical phenotype, with involvement of either single or multiple organ systems 
and the consequent clinical features (table 1). The age of presentation also varies widely, ranging 
from neonatal onset with fulminant lactic acidosis, to relatively mild disease in old age. 
Highly energetic tissues including skeletal muscle and nervous system are the most commonly 
affected due to their greater reliance on mitochondrial ATP synthesis. However, any organ system 
can be affected and one of the “red flags” alerting clinicians to the potential for a mitochondrial 
disorder is the association of neurological or muscular symptoms with concurrent or subsequent 
multi-organ involvement. The occurrence of muscle or central nervous system disease with 
involvement of two or more other organ systems, or any combination of disease affecting three or 
more organ systems should prompt consideration of mitochondrial disease. The multitude of 
potential presenting features means that mitochondrial diseases may be encountered by numerous 
medical specialists.  
Mitochondrial diseases are also progressive, with fluctuation and deterioration expected over time, 
with the potential for additional organ systems to be involved as time progresses. Progressive 
involvement of neuromuscular symptoms will often present with neurological regression in the 
developing child, and progressive loss of skills at any age. 
 
Phenotypic syndromes 
Certain clinically distinct clusters of symptoms and features are recognised as phenotypic 
mitochondrial syndromes.  Recognition of a mitochondrial syndrome can lead directly to a specific 
genetic diagnosis. It is, however, well recognised that the same genetic mutation or deletion can give 
rise to varied phenotypes, and conversely certain phenotypes can be caused by mutations in a range 
of different genes.  
Leigh syndrome and Leigh-like syndrome are infantile onset mitochondrial encephalopathies 
associated with bilateral symmetrical brain lesions particularly affecting the basal ganglia, thalamus 
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and brain stem. Affected individuals usually present in the first year of life with developmental 
regression, respiratory abnormalities, feeding difficulties and frequently with ophthalmic 
involvement (nystagmus, retinal dysfunction, ophthalmoplegia).[7,8] The genetic basis of these 
disorders is diverse, encompassing both nuclear and mtDNA mutations involving at least 89 different 
genes.[9] Originally a post mortem pathological diagnosis, typical in vivo MRI patterns are now the 
cornerstone of diagnosis of Leigh syndrome. 
Alpers disease is defined by progressive neurodegeneration, refractory seizures and liver 
dysfunction. It is usually caused by mutations in the nuclear gene POLG which encodes the catalytic 
subunit of DNA polymerase gamma (pol) which is required for the correct replication of mtDNA.[10] 
Dysfunction of pol leads to progressive depletion of mtDNA with subsequent mitochondrial 
dysfunction. Valproate toxicity is well recognised and this should be avoided in patients with this 
diagnosis. 
Mitochondrial Recessive Ataxia Syndrome (MIRAS) is one of the ataxia neuropathy spectrum 
disorders also caused by specific mutations in POLG.[11] This group of disorders is characterised by 
ataxia and neuropathy, variably associated with an encephalopathy with seizures. 
MELAS syndrome is the combination of mitochondrial Myopathy, Encephalopathy, Lactic Acidosis 
and Stroke-like episodes, with the majority of cases being caused by a common mtDNA mutation 
(m.3243A>G) in the mtDNA gene encoding a mitochondrial leucine transfer RNA (tRNA).[12]  Stroke-
like episodes are typically heralded by migraine headache, vomiting and seizures. Other clinical 
features include cognitive decline, ataxia, deafness, optic atrophy, short stature, diabetes and 
hypertrophic cardiomyopathy. The vast majority of individuals with the m.3243A>G mutation never 
develop strokes and have other clinical problems, most commonly maternally inherited diabetes and 
deafness.[13] 
MERRF describes the phenotype of Myoclonic Epilepsy and Ragged Red Fibres, the latter being a 
histopathological description of the appearances on muscle biopsy. MERRF is often caused by a 
mutation in the mtDNA gene encoding the tRNA for lysine, and is one of the disorders specifically 
associated with epilepsy phenotypes, often with ataxia.[14] Some patients have additional visual, 
audiological and cardiac involvement. 
Pearson syndrome is comprised of infantile onset sideroblastic anaemia (often transfusion 
dependent), lactic acidosis and variable pancreatic exocrine dysfunction.[15] It is associated with a 
sporadic large deletion in the mtDNA. Many infants do not survive and succumb to liver failure or 
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overwhelming acidosis in the first few years of life, but those who do live beyond infancy inevitably 
develop features of the Kearns-Sayre Syndrome.[16] 
Kearns-Sayre Syndrome (KSS), also caused by a large mtDNA deletion, may follow Pearson 
syndrome or present later without preceding anaemia, with onset before 20 years of age with ptosis, 
progressive external ophthalmoplegia (PEO) and pigmentary retinopathy.[17] Cardiac conduction 
defects, cerebellar ataxia and cerebral folate deficiency are other features.[16] 
Progressive External Ophthalmoplegia (PEO) is a feature of several disorders or can occur in 
isolation, and is often associated with mtDNA deletions, which may be single (sporadic) or multiple 
(secondary to autosomal dominant or recessive nuclear gene mutations). 
Leber hereditary optic neuropathy (LHON) occurs due to specific mtDNA mutations giving rise in 
adolescence or adult life to painless visual loss, usually an isolated phenomenon affecting both eyes 
sequentially. 
Neuropathy, Ataxia, Retinitis Pigmentosa (NARP) is often due to mutations in the mtDNA gene MT-
ATP6 encoding a subunit of ATP synthase. Individuals with high loads of the same mutations 
(typically >90%) present with maternally inherited Leigh syndrome. 
Mitochondrial Neuro-Gastro-Intestinal Encephalopathy (MNGIE) presents with gastrointestinal 
dysmotility, peripheral neuropathy and eye involvement, and is caused by mutations in the nuclear 
gene TYMP that encodes thymidine phosphorylase.[18] This results in a mtDNA depletion syndrome. 
The enzyme deficiency results in abnormal blood and urinary thymidine and deoxyuridine 
concentrations, and so blood/urine purine/pyrimidine analysis can suggest the diagnosis. 
Myopathy, Lactic Acidosis and Sideroblastic Anaemia (MLASA) is a rare autosomal recessive 
disorder predominantly affecting the skeletal musculature and bone marrow. It is usually caused by 
a defect of the YARS2 mitochondrial aminoacyl tRNA-synthetase or the PUS1 tRNA pseudo-
uridinylation enzyme, both of which are involved in mitochondrial translation.[19] 
Reversible Disorders 
While most mitochondrial disorders are considered progressive, a small number display a reversible 
phenotype. Such disorders include the infantile reversible myopathy due to the mtDNA mutation 
m.14674T>C/G in the MT-TE gene encoding the tRNA for glutamate, and reversible infantile liver 
disease due to mutations in TRMU encoding an enzyme that functions in normal mitochondrial tRNA 
modification.[20] Prompt recognition of these rare reversible disorders may enable the appropriate 
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continuation of  supportive treatment (such as prolonged ventilation) with the anticipation of 
subsequent recovery. 
 
Investigation of Mitochondrial Disease 
If a mitochondrial disorder is suspected, investigations aim firstly to provide additional evidence 
(clinical, biochemical, radiological) for mitochondrial disease, then secondly attempt to identify a 
specific genetic basis for the disease, and thirdly to evaluate for multi-system effects and in 
particular to detect treatable complications. In practice these three aims are addressed 
simultaneously. 
 
Multi-system evaluation 
Careful clinical evaluation may reveal multi-system dysfunction, and if signs or symptoms become 
evident specific investigations will be warranted. Table 2 includes examples of investigations that 
may be indicated in clinical baseline evaluation and on-going monitoring. 
 
Specific Metabolic Biochemistry 
Lactate may be elevated in blood and cerebrospinal fluid in mitochondrial disorders, but normal 
lactate levels do not exclude the possibility of a mitochondrial disorder. Measurement of lactate pre- 
and post-prandially can be useful in distinguishing mitochondrial disorders from disorders affecting 
glycogen metabolism. Lactate is the end product of anaerobic respiration (glycolysis), being 
reversibly converted from pyruvate by lactate dehydrogenase (LDH). Dysfunction of the respiratory 
chain results in impaired aerobic respiration, while the ratio of NADH to NAD+ (reflecting the 
abnormal mitochondrial redox status) is increased, driving the production of lactate. Measurement 
of the lactate/pyruvate ratio can help distinguish respiratory chain dysfunction from defects in 
earlier steps in pyruvate metabolism, notably pyruvate dehydrogenase deficiency. Lactate may be 
artefactually increased if a blood sample is difficult to obtain. Lactate may be increased secondary to 
tissue hypoxia of any cause including sepsis or significant hypotension. Neonatal lactic acidosis is 
common after a hypoxic-ischaemic insult, but would be expected to normalise over a few days. 
Elevated CSF lactate is also seen in non-mitochondrial brain diseases such as encephalitis, however 
an elevated CSF lactate without evidence of an alternative brain insult or recent seizures is 
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suspicious for mitochondrial disease. The same applies to lactate detected non-invasively by 
magnetic resonance spectroscopy of the brain. 
Plasma amino acids may show an elevated alanine concentration, again reflecting chronically 
increased pyruvate and lactate levels. Proline may also be elevated, while decreased citrulline may 
be seen in MELAS and NARP syndromes.[21,22] 
Plasma acylcarnitines may be helpful in differentiating from other causes of lactic acidosis, including 
long chain fatty acid oxidation defects and organic acidaemias, and may also identify specific 
metabolites in disorders of flavin metabolism and disorders causing toxic damage to the respiratory 
chain, such as ethylmalonic acidaemia and HIBCH and ECHS1 deficiencies.[23,24] 
Urine organic acid analysis may reveal elevated lactate and associated metabolites; intermediates of 
the TCA cycle, and ethylmalonic acid, may be seen as a non-specific indicator of mitochondrial 
dysfunction. 3-methylglutaconic aciduria is seen in a range of disorders including Barth 
syndrome.[25] Methylmalonic aciduria may be seen in SUCLA2  deficiency and related disorders.[26] 
Biotinidase activity detects biotinidase deficiency, which should be ruled out as this is easily treated 
with biotin supplementation, and is included in routine newborn screening in some countries.  
Novel biomarkers that have been reported to be elevated in mitochondrial disease include 
fibroblast growth factor 21 (FGF21) and growth and differentiation factor 15 (GDF15), but these are 
neither specific for mitochondrial disease nor are they elevated in all cases.[27,28] 
 
Neuroimaging 
Magnetic resonance imaging (MRI) is a powerful tool for evaluating brain involvement. Brain imaging 
may be undertaken during the investigation of a child with developmental issues, seizures or for 
other reasons, and certain features may give rise to the suspicion of mitochondrial disease. The 
central nervous system features seen in neuroradiological examination of mitochondrial disorders 
are diverse (figure 2). Typical features of Leigh syndrome include bilateral symmetrical signal 
abnormality in the basal ganglia (figure 2b) and brain stem. White matter may be diffusely abnormal 
(leukodystrophy) in a number of mitochondrial disorders including complex I (figure 2a) and complex 
II deficiency;[29] there can be non-specific cerebral atrophy; progressive cerebellar atrophy may be 
seen in mitochondrial disease but is not specific for this. Specific patterns of brain involvement may 
be associated with specific genotypes, including leukoecenphalopathy with brainstem and spinal 
cord involvement with elevated lactate (LBSL, associated with DARS2 mutations).[30]  Infarcts that 
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do not correspond to an arterial territory are a hallmark of MELAS syndrome  (figure 2c,d).[12] 
Structural brain abnormalities may be seen for example in pyruvate dehydrogenase complex (PDH) 
deficiency.[31]   
 
Muscle Biopsy 
Historically a muscle biopsy (either open surgical, or with large-bore needle biopsy) for 
histopathological tests and functional enzyme assays has been an important investigation for 
suspected mitochondrial diseases, although more recently the advent of more rapid genetic testing 
with next generation sequencing has superseded the need for a muscle biopsy in some situations. 
However a muscle biopsy may be helpful in differentiating from other causes of myopathy. 
Histochemistry 
Histochemical findings can be suggestive of mitochondrial disease, including the detection of ragged 
red fibres on the modified Gomori trichrome stain, or the observation of cytochrome c oxidase-
negative fibres. Non-specific findings include excess lipid deposition and mitochondrial 
ultrastructural changes on electron microscopic examination. Recently, a modified 
immunohistochemical technique known as quadruple OXPHOS immunofluorescence has been 
reported to provide more quantitative data about oxidative phosphorylation function.[32] 
Occasionally cardiac muscle biopsies undertaken to investigate an unexplained cardiomyopathy 
reveal features suggestive of mitochondrial disease, including giant mitochondria and abnormal 
mitochondrial ultrastructural appearances.  
Respiratory Chain Enzymology 
Spectrophotometric assays of complexes I-IV in a frozen muscle homogenate assess the function of 
the respiratory chain complexes and can identify either multiple or isolated complex deficiencies. 
Combined assay of complexes I+III or II+III indirectly assesses muscle coenzyme Q10 (CoQ10) which 
shuttles electrons between these two complexes, and muscle CoQ10 can also be quantified directly. 
Complex V can be assayed by Polarographic analysis of fresh muscle mitochondria or by Blue native 
gel assay of frozen muscle homogenate.  
Isolated complex deficiencies (e.g. of complex I) are often caused by mutations in a gene encoding 
either one of the structural subunits of the complex or an associated assembly factor, and 
identification of a specific isolated complex deficiency can help direct further targeted genetic 
analysis. 
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Mitochondrial DNA depletion syndromes are caused by nuclear gene defects affecting genes 
responsible for the maintenance and replication of the mtDNA, including POLG, TK2, RRM2B and 
DGUOK (figure 1a). These result in multiple deficiencies of the respiratory chain complexes. Similarly, 
disorders affecting mitochondrial DNA transcription or translation can result in multiple complex 
deficiencies. Since complex II is entirely encoded by nuclear genes it is not primarily affected in 
disorders of mtDNA (although complex II activity may be decreased secondarily if the muscle is 
severely compromised). 
A skin biopsy may be obtained either as a punch biopsy or at the time of an open muscle biopsy, to 
obtain cultured fibroblasts. These can be used to assess oxidative phosphorylation function, e.g. by 
microscale oxygraphy, or to assay PDH and pyruvate carboxylase activity; PDH can also be assayed in 
the muscle sample.[31] 
It should be noted that muscle respiratory chain enzymology may be normal in a patient with 
genetically confirmed mitochondrial disease, for example where the tissue-specific phenotype does 
not involve muscle. 
 
Molecular Genetics 
The constellation of features from the clinical history, examination and results of initial biochemical 
and radiological investigations can direct analysis to specific candidate genes (e.g. screening for 
specific mtDNA mutations in MELAS, LHON or NARP syndromes, or for POLG mutations in Alpers 
syndrome). Particular patterns of respiratory chain enzyme complex deficiencies on muscle biopsy 
can also suggest groups of genes to be evaluated. The family history can suggest whether a nuclear 
gene defect (in a consanguineous family with multiple affected individuals on both sides of the 
pedigree) or a mtDNA defect (matrilineal pattern of inheritance) is more likely.  
Nuclear genes can be assessed with DNA extracted from blood. mtDNA mutation load varies from 
tissue to tissue, with highest levels of mutation heteroplasmy expected in affected tissues, and as a 
result mtDNA analysis is best performed on DNA extracted from an affected tissue, usually muscle 
DNA. However, in infants with severe mtDNA-encoded disease it is expected that the blood 
heteroplasmy level will be sufficiently high that analysis of blood DNA will detect mtDNA mutations.  
mtDNA analysis may start with analysis for large scale deletions or rearrangements, followed by 
specific common point mutation analysis, and finally full mtDNA sequencing. Individual candidate 
nuclear genes can be Sanger-sequenced directly. However the genetic complexity underlying 
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mitochondrial disease, with hundreds of candidate genes, means that this is an inefficient approach 
and increasingly next generation sequencing is being employed to evaluate larger panels of genes or 
whole exomes or genomes. Furthermore, as we move away from muscle biopsies as the gold 
standard diagnostic test, novel bioinformatics tools will be needed to help confirm pathogenicity of 
observed genetic variants.[9]  
Parental blood DNA samples are required to evaluate nuclear gene mutations identified in the 
proband; DNA samples from blood and urinary cellular sediments from the mother may be 
evaluated in the case of mtDNA encoded disorders to determine maternal levels of mtDNA mutation 
heteroplasmy. Subsequently it may be appropriate to undertake cascade family screening. 
Identification of the mode of inheritance can also help inform discussions about recurrence risk for 
future children and potential reproductive options.  Involvement of clinical genetics teams is 
important. 
 
 
Management of mitochondrial disorders 
The management of a child with mitochondrial disease requires the input of many different 
healthcare professionals (including metabolic physicians, neurologists, cardiologists, 
endocrinologists, gastroenterologists, nephrologists, intensivists, ophthalmologists, audiological 
physicians, community paediatricians, dietitians, nurses, physiotherapists, speech and language 
therapists and psychologists) collaborating to optimise clinical management, addressing the 
numerous complications that arise. Ensuring good nutrition, monitoring growth and developmental 
parameters, providing appropriate support for education and physical mobility needs are all critical 
aspects of management. 
General supportive interventions need to be tailored according to the patient-specific problems that 
arise, and can span numerous medical specialities (Table 3). Some invasive interventions such as 
solid organ transplantation may not be considered appropriate in the context of progressive multi-
system disease, but may be considered if there is an isolated single-organ failure in limited 
circumstances.  
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Specific therapies 
There is also a growing evidence base for specific therapies for mitochondrial disorders,[33] 
although the challenges of undertaking rigorous randomised controlled trials in such disparate and 
rare disorders is reflected in the relatively small number of high quality trials identified by the 
Cochrane review process.[34]    
Lactic acidosis 
Lactic acidaemia if severe can result in acidosis; in such situations appropriate use of sodium 
bicarbonate to normalise acid-base status is required. Dichloroacetate stimulates PDH activity by 
inhibition of PDH kinase and can decrease lactate levels. However, the impact on long term outcome 
is not clear, and long term use may be associated with peripheral nerve toxicity.[34,35] 
Treatable disorders 
There is a small group of readily treated disorders that respond to specific therapies, and these 
should be identified promptly and treatment initiated in a timely manner.[5] These include use of 
CoQ10 supplements for CoQ10 biosynthesis defects; riboflavin (vitamin B2) in riboflavin-responsive 
disorders such as ACAD9 or FLAD1 deficiency;[36,37] biotin in biotinidase deficiency; and 
combinations of biotin and thiamine in high doses for biotin-thiamine responsive basal ganglia 
disease.[38,39].  Thiamine is given if PDH deficiency is suspected as some defects are thiamine 
responsive.  A deficiency of 5-methyltetrahydrofolate (the major transport form of folic acid) has 
been reported in a several mitochondrial disorders including KSS and is treatable with regular folinic 
acid. Supplementation with these therapies may be initiated empirically while awaiting final 
diagnostic investigations. 
Arginine in MELAS syndrome 
There is growing evidence for the use of arginine therapy in MELAS syndrome for both acute 
treatment and prevention of stroke-like episodes.[12] Arginine is required for nitric oxide synthesis, 
and the observation of low arginine and citrulline levels in patients particularly during acute stroke 
episodes supports the hypothesis that vasodysregulation contributes to the aetiology of the stroke-
like episodes.  
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Potentially detrimental drugs 
Certain drugs have the potential to be detrimental in the context of a mitochondrial disorder and 
should be avoided or used with caution.[40] These include sodium valproate (risk of hepatotoxicity, 
and contra-indicated in patients with POLG mutations), and anaesthetic agents such as propofol.[41] 
 
Novel therapies under evaluation 
Antioxidant therapy 
Excessive production of reactive oxygen species occurs when the respiratory chain is dysfunctional, 
and it is thought that consequent oxidative stress may play an important role in the pathophysiology 
of mitochondrial disorders.[35] Numerous antioxidants have been used in the treatment of 
mitochondrial diseases. Therapies include CoQ10,[42] and the related compounds idebenone [33] 
and EPI-743.[43] N-acetylcysteine is a cysteine donor and can replenish glutathione, although 
evidence for therapeutic efficacy is lacking. Vitamin C, E and chemical analogues are also being 
evaluated. 
Stimulating mitochondrial biogenesis 
Approaches aimed at increasing mitochondrial biogenesis have been evaluated, using both 
pharmacological approaches such as bezafibrate (a PPAR activator) or resveratrol (a SIRT1 sirtuin 
activator) as well as dietary approaches via the ketogenic diet, which all result in up-regulation of 
mitochondrial gene expression and subsequent mitochondrial biogenesis.[35] Recently, decanoic 
acid, a C10 fatty acid produced in response to the ketogenic diet, has been found in vitro to 
stimulate mitochondrial biogenesis,[44] and may have efficacy in primary mitochondrial disease 
although formal clinical trials are still needed.[45]    
Other novel therapies  
Other novel therapeutic approaches include: targeting the mitochondrial membrane and its complex 
lipids;[46] replacing nucleosides in mtDNA depletion disorders that are associated with nucleoside 
deficiency; [47] and gene therapy approaches including recoding mtDNA-encoded genes to be 
expressed in the nuclear genome (allotopic gene expression), “conventional” viral-vector mediated 
nuclear-targeted gene therapies, and selective destruction of mutant mtDNA using restriction 
endonuclease technologies (see [5]).   
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Future reproductive options 
While detailed comment is beyond the scope of this review, parents of a child with mitochondrial 
disease, or who are known carriers of either nuclear or mitochondrial gene mutations, may consider 
a number of options for future children, including antenatal testing, pre-implantation genetic 
diagnosis [48] or potentially “mitochondrial donation” technologies [49] although these methods 
have generated  medical ethical debate.   
 
Conclusions 
Understanding of normal mitochondrial physiology has been furthered through the insights gained 
from the clinical and laboratory investigation of patients with diverse mitochondrial genetic 
disorders. Early consideration of the possibility of a mitochondrial disorder, followed by careful 
clinical assessment and biochemical, radiological and genetic investigation can lead to a diagnosis of 
mitochondrial disease. Diagnosis will then prompt symptomatic, and in some situations, disease 
modifying, therapies. Novel therapies in the pipeline aim to further improve the prognosis for 
children affected by these frequently devastating disorders.   
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Tables 
 
Table 1: Diverse clinical features of mitochondrial disease 
Central nervous system Strokes 
Seizures 
Neurological/ developmental regression 
Neuroradiological features 
Peripheral nervous system Peripheral neuropathy 
Eyes Ptosis 
Ophthalmoplegia 
Nystagmus 
Visual disturbance 
Retinitis pigmentosa 
Hearing Sensorineural deafness/ hearing impairment 
Endocrine Growth hormone deficiency 
Thyroid or parathyroid dysfunction 
Multiple hormonal deficiencies 
Pancreatic Diabetes mellitus 
Exocrine insufficiency 
Hepatic Liver failure 
Gastrointestinal Enteropathy, dysmotility, pseudo-obstruction 
Muscular Myopathy 
Haematological Anaemia 
Marrow failure 
Renal Tubular dysfunction 
Progressive renal impairment 
Steroid-resistant nephrotic (primary coenzyme Q10 deficiency) 
Cardiac Conduction defects 
Cardiomyopathy 
Dermatological Hypertrichosis 
Pili torti (some complex III assembly defects) 
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Table 2: Multi-system evaluation 
Central nervous system Neuroimaging: MRI, CT for acute stroke episodes 
Electroencephalogram (EEG) 
Peripheral nervous system Nerve conduction studies, electromyography 
Eyes Ophthalmological referral 
Visual evoked potentials/ electroretinogram 
Hearing Audiological assessment 
Speech and language evaluation 
Endocrine Growth parameters 
Hormone assays (growth hormone, thyroid, parathyroid, 
adrenal function) 
Pancreatic Blood glucose monitoring, HbA1c 
Faecal elastase (exocrine function) 
Amylase, lipase 
Hepatic Hepatic ultrasound 
Liver function tests 
Gastrointestinal Assessment of swallow 
Growth monitoring 
Muscular Physiotherapy evaluation 
Haematological Full blood count and film 
Renal Tubular function assays (urine NAG/creatinine and 
RBP/creatinine) 
Renal function tests 
Cardiac ECG 
Echocardiogram 
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Table 3: Examples of multi-system supportive interventions 
System Feature Treatment 
Central nervous 
system 
Seizures Anticonvulsants 
Stroke-like episodes 
(MELAS) 
Arginine 
Dysphagia SALT intervention, gastrostomy 
Eyes Ptosis 
Visual dysfunction 
Brow suspension 
Visual aids 
Hearing Hearing impairment Hearing aids, cochlear implant 
Endocrine Hormone deficiency Appropriate hormone supplementation 
Pancreatic Diabetes 
Pancreatic exocrine 
insufficiency 
Insulin or oral antidiabetic agents 
Enzyme supplementation 
Hepatic Liver dysfunction, 
failure 
Consider hepatic transplant if isolated liver 
disease 
Gastrointestinal Dysmotility, swallow 
dysfunction 
Gastrostomy 
Enteral feeds 
Consider parenteral nutrition 
Muscular Myopathy Physiotherapy, appropriate mobility aids and 
supports 
Haematological Anaemia Transfusion 
Iron/ haematinics 
Renal Tubular dysfunction 
 
Electrolyte supplementation 
Consider renal replacement therapy 
Cardiac Conduction anomalies 
Cardiomyopathy 
Pacing, Implantable defibrillator 
Medical treatment (Lisinopril, beta blockers) 
Consider cardiac transplant 
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Figures 
Figure 1 A: Nuclear genes associated with mitochondrial disease (Adapted from [5]) 
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Figure 1 B: Mitochondrial DNA (mtDNA) genes, all associated with mitochondrial disease. 
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Figure 2: Neuroradiological features in mitochondrial diseases. 
A: Axial T2-weighted MRI image from infant with complex I deficiency due to NDUFV2 mutations showing widespread symmetrical increased white matter 
signal (leukodystrophy) (arrow) 
B: Axial T2-weighted MRI image from infant with Leigh disease due to mtDNA MT-ND3 mutation, showing increased signal in basal ganglia (arrow) and 
thalami (arrowhead) 
C: Axial CT scan from child with MELAS syndrome showing acute left parieto-occipital infarct with signal hypointensity (arrows). 
D: Axial T2-weighted MRI image from same child as (C), obtained several months after acute insult, showing cortical/subcortical volume loss in infarcted 
region (arrow), ventriculomegaly, and also abnormal striatum (arrowhead).  
 
24 
 
 
 
